
Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.

Jean-Yves Blay, MD, PhD, professor of Medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the heterogeneity of soft tissue sarcoma.

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

October 17th 2016

February 6th 2017

March 21st 2017